|
Dec 8
|
Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG
|
|
Dec 7
|
Will There Be a Recession in 2024?
|
|
Dec 7
|
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
|
|
Dec 6
|
Pfizer CEO slams presidents of elite colleges over ‘despicable’ antisemitism
|
|
Dec 6
|
Pfizer (PFE) Declines More Than Market: Some Information for Investors
|
|
Dec 6
|
UPDATE 4-AbbVie to buy drug developer Cerevel for $8.7 billion
|
|
Dec 6
|
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
|
|
Dec 6
|
Column: A bogus new attack on COVID vaccines from Texas' least credible politician
|
|
Dec 5
|
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
|
|
Dec 5
|
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
|
|
Dec 5
|
Pfizer’s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals
|
|
Dec 5
|
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
|
|
Dec 5
|
12 Best Healthcare Dividend Stocks To Buy Now
|
|
Dec 5
|
Pfizer, after delay, completes enrollment in Lyme vaccine trial
|
|
Dec 5
|
Pfizer (NYSE:PFE) shareholders have endured a 40% loss from investing in the stock a year ago
|
|
Dec 4
|
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
|
|
Dec 4
|
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
|
|
Dec 4
|
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
|
|
Dec 4
|
ProPicks: Beat the S&P 500 with our cutting-edge AI-powered stock selection
|
|
Dec 3
|
Is Pfizer Stock a Buy Now?
|